ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DHODH/TEAD4 Inhibitor CP-383

Its studies are mostly in Colorectal Neoplasms, led by Tasca Therapeutics.

Furthest: phase 2, since May 20, 20251 company-led study, 1 open or runningNext primary completion: Aug 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tasca Therapeutics11 open or runningphase 2since May 20, 2025May 20, 2025Aug 15, 2028phase 2 · NCT07030257

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2025First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT07030257 · 150 planned · United States

Ahead

  1. Aug 15, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT07030257

TargetBeta

DHODH →TEAD4 →read by rule
“An orally bioavailable, dual inhibitor of dihydroorotate dehydrogenase (DHODH) and the TEA domain transcription factor 4 (TEAD4), ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07030257Colorectal Neoplasms · United States2RecruitingAug 15, 2028150

How it is read

Names in the registry

  • “CP-383”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.